Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799331 | 0.91 | TDP1 (0.60) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL22053950 | 0.91 | TDP1 (0.58) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL13060101 | 0.91 | TDP1 (0.58) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL700015 | 0.89 | KDM4E (0.48) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL13261104 | 0.89 | KDM4E (0.48) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL700291 | 0.89 | TDP1 (0.62) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL7587742 | 0.89 | TDP1 (0.54) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL21320724 | 0.87 | TDP1 (0.45) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL30034529 | 0.87 | LMNA (0.50) | TDP1KDM4EBLMPMP22ALOX15 | |
| SCHEMBL18793625 | 0.87 | TDP1 (0.54) | TDP1KDM4EBLMPMP22ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414795-A1 | PSMA TARGETED COMPOUNDS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2023-12-28 | — | — | US | claimed |
| US-11738099-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-29 | — | — | US | claimed |
| CN-116157159-A | Diagnosis and monitoring using off-domain-B fibronectin targeting probes | 凯斯西储大学 | 2023-05-23 | — | — | CN | claimed |
| EP-4161584-A2 | DIAGNOSIS AND MONITORING USING EXTRADOMAIN-B FIBRONECTIN TARGETED PROBES | Case Western Reserve University (US) | 2023-04-12 | — | — | EP | claimed |
| US-20220160903-A1 | PEPTIDE PET/SPECT PROBES SPECIFIC TO ONCOPROTEINS IN TUMOR EXTRACELLULAR MATRIX | CASE WESTERN RESERVE UNIVERSITY | 2022-05-26 | — | — | US | claimed |
| CN-113727737-A | Tumor extracellular matrix oncoprotein specific peptide PET/SPECT probe | 卡斯西部储备大学 | 2021-11-30 | — | — | CN | claimed |
| US-20210275695-A1 | MOLECULAR PROBES AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-09 | — | — | US | claimed |
| US-10925980-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-02-23 | — | — | US | claimed |
| US-20180311385-A1 | NOVEL KININ-BASED THERANOSTIC PROBES FOR SOLID CANCERS AND USES THEREOF | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SANTE ET HUMAINES, S.E.C. (CA) | 2018-11-01 | — | — | US | claimed |
| US-20180110886-A1 | MOLECULAR PROBES AND METHODS OF USE | CASE WESTERN RESERVE UNIVERSITY | 2018-04-26 | — | — | US | claimed |
| US-9011816-B2 | Fibronectin targeting contrast agent | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-04-21 | — | — | US | claimed |
| US-20120244070-A1 | FIBRONECTIN TARGETING CONTRAST AGENT | CASE WESTERN RESERVE UNIVERSITY | 2012-09-27 | — | — | US | claimed |
| US-20110236316-A1 | PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2011-09-29 | — | — | US | claimed |
| EP-2257314-A2 | PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF | University of Utah Research Foundation (US) | 2010-12-08 | — | — | EP | claimed |
| US-20100284927-A1 | USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-11-11 | — | — | US | claimed |
| US-7745590-B1 | Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | claimed |
| WO-2009111273-A2 | PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-09-11 | — | — | WO | claimed |
| EP-2081979-A2 | DENDRIMERS AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2009055542-A1 | USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2008121153-A2 | DENDRIMERS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244070-A1 | FIBRONECTIN TARGETING CONTRAST AGENT | FN1, CFD, VCAM1 | TDP1 3921/4885KDM4E 4542/4885BLM 2219/4885 |
| US-11738099-B2 | Molecular probes and methods of use | DDX21, FUS, DDIT3 | TDP1 424/4885KDM4E 2772/4885BLM 432/4885 |
| US-20230414795-A1 | PSMA TARGETED COMPOUNDS AND USES THEREOF | FOLH1, PSMA6, PSMA2 | TDP1 2678/4885KDM4E 2640/4885BLM 3132/4885 |
| US-20220160903-A1 | PEPTIDE PET/SPECT PROBES SPECIFIC TO ONCOPROTEINS IN TUMOR EXTRACELLULAR MATRIX | FN1, EDNRB, NGLY1 | TDP1 2777/4885KDM4E 4454/4885BLM 4443/4885 |
| US-20100284927-A1 | USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS | TSG101, SMARCE1, CD68 | TDP1 2248/4885KDM4E 3274/4885BLM 1953/4885 |
| US-10925980-B2 | Molecular probes and methods of use | EDNRB, FGB, FN1 | TDP1 2798/4885KDM4E 4632/4885BLM 3404/4885 |
| US-20210275695-A1 | MOLECULAR PROBES AND METHODS OF USE | EDNRB, FGB, FN1 | TDP1 2798/4885KDM4E 4632/4885BLM 3404/4885 |
| US-20180110886-A1 | MOLECULAR PROBES AND METHODS OF USE | EDNRB, FGB, FN1 | TDP1 2798/4885KDM4E 4632/4885BLM 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.